Synergistic interaction between platinum-based antitumor agents and demethylcantharidin
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要A novel series of TCM-platinum complexes [Pt(C8H8O5)(NH2R)(2)] 1-5, designed from incorporating demethylcantharidin, a modified component from a traditional Chinese medicine (TCM) with a platinum moiety was found to circumvent cisplatin resistance in mouse leukemia and human hepatocellular carcinoma. These properties are most likely due to the inclusion of the protein phosphatase 2A (PP2A)-inhibiting demethylcantharidin in the novel compounds. We have investigated the potential synergistic effect of combining demethylcantharidin with a platinum-based antitumor agent, such as cisplatin, carboplatin, or oxaliplatin in vitro against L1210 mouse leukemia and SK-Hep-1 human hepatocellular carcinoma, and in vivo against a SK-Hep-1 subcutaneous-inoculated xenograft in nude mice, using median effect analysis. Demethyleantharidin and the platinum antitumor agents were synergistic in all cell lines tested in vitro, and the most effective antiproliferative regimen was when demethylcantharidin was added 24 h before cisplatin. Synergistic antitumor activity was also demonstrated in vivo without undue toxicity; no excessive loss in mouse body weight or overt pathology were observed at the effective doses. The results support a new approach for augmenting cytotoxic effect of established Pt-based drugs with demethylcantharidin in treating human hepatocellular carcinoma and other solid tumors. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
著者To KKW, Ho YP, Au-Yeung SCF
期刊名稱Cancer Letters
出版年份2005
月份6
日期8
卷號223
期次2
出版社ELSEVIER IRELAND LTD
頁次227 - 237
國際標準期刊號0304-3835
電子國際標準期刊號1872-7980
語言英式英語
關鍵詞cytotoxicity; demethylcantharidin; platinum antitumor agents; protein phosphatase inhibitors; synergy
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2021-26-02 於 00:57